Avion Pharmaceuticals, LLC, announces strategic alliance with Albion® Laboratories, Inc.

Apr 22, 2014, 09:00 ET from Avion Pharmaceuticals, LLC

ATLANTA, April 22, 2014 /PRNewswire/ -- Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced their business partnership with Utah based Albion® Laboratories.  The collaboration will focus on the licensing of unique, patented API ingredients and future product development for Avion's women's health portfolio.

Over the past 50 years, Albion® has pioneered research with unique and natural mineral delivery systems that support improvements in mineral nutrition, leading to healthier lifestyles. Albion® develops intellectual property across several areas, including pharmaceutical-grade mineral nutrition and new mineral molecule forms for custom application. The alliance with Albion will positively align with Avion's new product initiatives in prenatal and post-natal health and its focus on researching women's health needs and matching products that deliver positive benefit for women of all ages and life stages. 

"Avion is relentless in the pursuit of innovation that will deliver improvements in products that support optimized lifestyles for patients" said Mike Sullivan, President of Avion Pharmaceuticals. "This relationship with Albion® will allow for continued development and commercialization of products that fill important gaps in nutrition."

Avion CEO Mark Pugh added, "Albion's expertise in mineral delivery systems and nutrition, married with Avion's strong association with the Ob/Gyn community, bodes positively for a bright future that supports ongoing advances and additions to our existing portfolio."

About Avion Pharmaceuticals, LLC.

Avion Pharmaceuticals, LLC., is a Specialty Pharmaceutical company formed to develop and market a portfolio of innovative products in the Women's Heath and Dermatology therapeutic areas.  Avion Pharmaceuticals focuses on identifying opportunities to acquire and enhance the market potential of innovative, commercially available therapeutics and late-stage development drugs to fulfill unmet medical needs. For additional information about Avion Pharmaceuticals please contact the company at 678-325-5188.





SOURCE Avion Pharmaceuticals, LLC